Skip to Content

Coloplast A/S ADR

CLPBY: PINX (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$62.60FftssStwpswtw

Coloplast's Impressive Track Record for Innovation Adds Up to a Narrow Moat

Business Strategy and Outlook

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented wound-care markets, but it remains a peripheral player there. We think Coloplast has dug itself a narrow moat thanks to consistent innovation in ostomy and continence care that has led to a dominant position in Europe. Since 2008, the firm has done an admirable job of trimming its cost structure as it focused on profitable growth. As a result of shifting the majority of its production to Hungary and China, Coloplast now enjoys a gross margin that beats that of rival ConvaTec by 1,600 basis points. Currently, Coloplast is altering its emphasis to enhance growth by entering new geographies,with an emphasis on the U.S.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CLPBY so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center